Category Archives: Topics

Latest Advances Targeting Neoantigens and Developing TCR-T Cell Therapies; Ziopharm Presents Preclinical Data from Their Hotspot TCR-T Library Program; Medigene’s PRAME-Specific TCR PD1-41BB Switch Receptor Could Treat a Broad Range of Liquid and Solid Tumors; AACR 2021 Day 6

On the final day of AACR 2021 Week I, two key TCR-T platform updates were presented from Ziopharm and Medigene, while different approaches for neoantigen discovery and TCR evaluation were explored in a panel discussion. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Latest NK Cell Therapy Advances Discussed in a Panel Session; Fate Tx Presents Preclinical Updates for Two iPSC-derived CAR-NKs; AACR 2021 Day 5

On the fifth day of AACR 2021 Week I, two key preclinical CAR-NK updates were reported from Fate Therapeutics, while the latest NK cell engineering approaches were reviewed during a panel discussion. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Switchable CAR-T Updates from Arcellx, GEMoaB, and AbClon; Carisma Therapeutics Presents Their CAR-Macrophage and CAR-Monocyte Programs; AACR 2021 Day 4

On the fourth day of AACR 2021 Week I, several key clinical / preclinical updates were presented from GEMoaB, Arcellx, AbClon, and Carisma Therapeutics. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Gilead Reports Innovative Biomarkers Associated with Clinical Outcomes in the Ph2 ZUMA-5 Trial; Carl June Explores Novel Approaches to Improve CAR-T Function; IL-2 Makes a Comeback with OrthoCARs; AACR 2021 Day 3

On the third day of AACR 2021 Week I, key clinical / preclinical updates were reported from Gilead (Kite) and Synthekine, while Carl June presented an overview of CAR-T engineering tools to improve efficacy and safety outcomes. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

First Patient Dosed in Allogene’s ALLO-715 + Nirogacestat Cohort in the Ph1 UNIVERSAL Trial

On Monday, April 12, Allogene and SpringWorks announced (press release) that the first patient has been dosed with ALLO-715 (BCMA CAR-T) + nirogacestat (GSI) in the Ph1 UNIVERSAL trial (r/r MM). Below, Celltelligence provides insights into Allogene’s and key competitor Precision Biosciences’s clinical progress combining a GSI with their lead BCMA CAR-T assets, while discussing other strategies currently under evaluation to improve BCMA-targeting CAR-T efficacy.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Can Allogene’s PD1 TurboCAR Overcome the TME? CRISPR Tx’s CTX130 CD70 KO Prevents CAR-T Exhaustion; Can TCR2’s CD70 and Allogeneic TRuC-Ts Outclass CAR-T Therapies? AACR 2021 Day 2

On the second day of AACR 2021 Week I, four key preclinical updates were presented from Allogene, CRISPR Therapeutics, and TCR2 Therapeutics. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Novel In-depth Product Characteristics for Kymriah and Yescarta Correlate with Patient Outcomes; Gracell’s Clinical Update for GC027 TruUCAR in T-ALL; Preliminary Results for TCR2’s Gavo-cel in Mesothelin Overexpressing Solid Tumors; AACR 2021 Day 1

On the first day of AACR Week I 2021, four key clinical updates were presented from Novartis, Gilead (Kite), Gracell, and TCR2 Therapeutics. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Gilead Files Tecartus’s sBLA in Adult R/R ALL; AUTO1 Receives PRIME Designation by the EMA; JNJ / Legend Complete Cilta-cel’s Rolling BLA in the US; BMS Files Abecma in Japan for R/R MM; Precision’s New CEO Transition Plan

Ahead of AACR, a series of cell therapy-related news items have been observed:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Autolus Pivots Manufacturing Away from the US; TCR2 Takes Over Autolus’s Rockville Facility; Is Confidence in AUTO1 Wavering?

On Monday, March 29, Autolus announced (press release) an update to their manufacturing strategy for the commercial supply of AUTO1 (CD19 CAR-T). Autolus aims to expand existing operations in the UK while terminating the lease for their US manufacturing facilities in Rockville, MD. Moreover, on the same day, TCR2 Therapeutics announced (press release) that they are seeking to accelerate commercial-scale manufacturing timelines by leasing a new manufacturing facility in Rockville, MD. Below, Celltelligence provides thoughts on Autolus’s manufacturing strategy, while contrasting Autolus’s possible headwinds with TCR2’s potential opportunities.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

First BCMA CAR-T Approved in the US for Multiple Myeloma; Will Abecma’s 33-day TAT and High Price Prevent Wide-Spread Adoption?

On Friday, March 26, BMS and bluebird bio announced (press release) that the FDA approved Abecma (idecabtagene vicleucel) for the treatment of ≥5L r/r MM (i.e. after completing at least 4 lines of prior therapy). Below, Celltelligence provides thoughts on Abecma’s higher list price and longer TAT vs. approved CD19 CAR-Ts, while discussing Abecma’s potential messaging strategy.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.